Abstract
Patients with thalassemia major requiring regular blood transfusions accumulate iron that is toxic to the heart, liver, and endocrine systems. The following prospective, randomized trial was carried out to determine the effectiveness, in children and young adults, of combined deferiprone (DFP) and deferoxamine (DFO) in reducing transfusional iron overload compared to either drug alone and to assess the safety and tolerability of DFP. Sixty-six patients were randomized into three treatment arms: daily DFP combined with DFO twice weekly; daily DFP only; and DFO only 5 days/week. Fifty-six patients completed the 54 weeks and were assessed by different indices. A significant reduction of liver iron concentration and serum ferritin was observed in all three arms while significant reduction of liver iron score was observed in patients on combination therapy only. Cardiac function did not significantly change in any arm. Compliance improved in patients who received combined therapy. Toxicity of DFP was mild to moderate and acceptable; most commonly, transient arthropathy and nausea/vomiting were observed. Thus, combination therapy has shown to be effective in reducing iron overload in thalassemia patients.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Anderson LJ, Wonke B, Prescott E, Holden S, Walker JM, Pennell DJ (2002) Comparison of effects of oral deferiprone and subcutaneous desferrioxamine on myocardial iron levels and ventricular function in beta thalassemia. Lancet 360:516–520
Angelucci E, Brittenham GM, McLaren CE, Ripalti M, Baronciani D, Giardini C, Galimberti M, Polchi P, Lucarelli G (2000) Hepatic iron concentration and total body iron stores in thalassemia major. N Engl J Med 343:327–331
Balveer K, Pyar K, Wonke B (2002) Combined oral and parental iron chelation in beta thalassemia major. Med J Malaysia 55:493–497
Borgna-Pignatti C, Cappellini MD, De Stefano P, Del Vecchio GC, Forni GL, Gamberini MR, Ghilardi R, Piga A, Romeo MA, Zhao H, Cnaan A (2006) Cardiac morbidity and mortality in deferoxamine- or deferiprone-treated patients with thalassemia major. Blood 107:3733–3737
Cohen AR, Galanello R, Piga A, Dipalma A, Vullo C, Trica F (2000) Safety profile of the oral iron chelator deferiprone: a multicenter study. Br J Haematol 108:305–312
Daar S, Pathare AV (2006) Combined therapy with desferrioxamine and deferiprone in beta thalassemia major patients with transfusional iron overload. Ann Hematol 85:315–319
Giardina PJ, Grady RW (2001) Chelation therapy in b-thalassemia: an optimistic update. Sem Hematol 38:360–366
Grady RW, Berdoukas V, Rachmilewitz E, Galanello R, Borgna-Pignatti C, Giardina PJ (2000) Iron chelation therapy: optimizing chelation therapy: combining deferiprone and desferrioxamine [abstract]. Blood 96(Suppl 1):604a
Hoffbrand AV (2005) Deferiprone therapy for transfusional iron overload. Best practice and research. Clinical Haematology 18:299–317
Kattamis A, Ladis V, Berdousi H, Kelekis NL, Alexopoulou E, Papasotiriou I, Drakaki K, Kaloumenou I, Galani A, Kattamis C (2006) Iron chelation treatment with combined therapy with deferiprone and deferioxamine: a 12-month trial. Blood Cells Mol Dis 36:21–25
Link G, Konijn AM, Breuer W, Cabantchik ZI, Hershko C (2001) Exploring the “iron shuttle” hypothesis in chelation therapy: effects of combined deferoxamine and deferiprone treatment in hypertransfused rats with labeled iron stores and in iron-loaded rat heart cells in culture. J Lab Clin Med 138:130–138
Mourad FH, Hoffbrand AV, Sheikh-Taha M, Koussa S, Khoriaty AI, Taher A (2003) Comparison between desferrioxamine and combined therapy with desferrioxamine and deferiprone in iron overloaded thalassemia patients. Br J Haematol 121:187–189
Origa R, Bina P, Agus A, Crobn G, Defraia E, Dessi C, Leoni G, Muroni Pier P, Galanello R (2005) Combined therapy with deferiprone and desferrioxamine in thalassemia major. Hematologica 90:1309–1314
Peng CT, Chow KC, Chen JH, Chiang YP, Lin TY, Tsai CH (2003) Safety monitoring of cardiac and hepatic systems in beta-thalassemia patients with chelating treatment in Taiwan. Eur J Haematol 70:392–397
Pennell DJ, Berdoukas V, Karagiorga M, Ladis V, Piga A, Aessopos A, Gotsis ED, Tanner MA, Smith GC, Westwood MA, Wonke B, Galanello R (2006) Randomized controlled trial of deferiprone or deferoxamine in beta-thalassemia major patients with asymptomatic myocardial siderosis. Blood 107:3738–3744
Tanner MA, Galanello R, Dessi C, Smith GC, Westwood MA, Agus A, Roughton M, Assomull R, Nair SV, Walker JM, Pennell DJ (2007) A randomized, placebo-controlled, double-blind trial of the effect of combined therapy with deferoxamine and deferiprone on myocardial iron in thalassemia major using cardiovascular magnetic resonance. Circulation 115:1876–1884
Wonke B, Wright C, Hoffbrand AV (1998) Combined therapy with deferiprone and desferrioxamine. Br J Haematol 103:361–364
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
El-Beshlawy, A., Manz, C., Naja, M. et al. Iron chelation in thalassemia: combined or monotherapy? The Egyptian experience. Ann Hematol 87, 545–550 (2008). https://doi.org/10.1007/s00277-008-0471-2
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00277-008-0471-2